Top Markets
Coin of the day
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Rank in Stocks #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Share Price
$0.20876331
Market Cap
$1.38M
Change (1 day)
1.15%
Change (1 year)
-64.84%
Country
FR
Trade IntegraGen SA (ALINT)

Category

P/E ratio for IntegraGen SA (ALINT)
P/E ratio as of July 2026 TTM: -0.44
According to IntegraGen SA latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.44. At the end of 2023 the company had a P/E ratio of -34.49.
P/E ratio history for IntegraGen SA from 2008 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.44 -97.03%
2024 -14.87 -56.90%
2023 -34.49 -98.49%
2022 -2.29K -580.43%
2021 475.99 -1,410.17%
2020 -36.33 58.02%
2019 -22.99 265.16%
2018 -6.30 -66.77%
2017 -18.95 83.80%
2016 -10.31 -30.43%
2015 -14.82 -41.54%
2014 -25.35 240.82%
2013 -7.44 -55.44%
2012 -16.69 12.86%
2011 -14.79 89.29%
2010 -7.81 -20.84%
2009 -9.87 10.70%
2008 -8.92 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
11.47 -2,699.77%
DK
29.20 -6,721.81%
US
14.66 -3,424.54%
US
31.95 -7,345.17%
BE
51.86 -11,859.75%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.